Given the integral role of P53 in many cellular processes, it seems unlikely that targeting P53 or the pathway directly is likely to yield significant therapeutic benefits without substantial off-target effects, though targeted delivery to tumor cells is an active field of development (reviewed extensively by Hsu et al. [76]). This evidence concerns the gene TP53 and neoplasm.